{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T03:33:41Z","timestamp":1790393621932,"version":"4.1.0"},"reference-count":139,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1053\/j.seminhematol.2025.08.002","type":"journal-article","created":{"date-parts":[[2025,8,19]],"date-time":"2025-08-19T14:49:06Z","timestamp":1755614946000},"page":"131-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Germline predispositions to myeloid malignancies: Across the lifespan"],"prefix":"10.1053","volume":"62","author":[{"given":"Himachandana","family":"Atluri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Swaroop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy A.","family":"Godley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2025.08.002_bib0001","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1182\/blood.2021011354","article-title":"Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML","volume":"139","author":"Yang","year":"2022","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0002","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1038\/s41375-021-01137-0","article-title":"Germline variants drive myelodysplastic syndrome in young adults","volume":"35","author":"Feurstein","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0003","doi-asserted-by":"crossref","first-page":"3245","DOI":"10.1038\/s41375-021-01246-w","article-title":"Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer","volume":"35","author":"Singhal","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1182\/blood.V122.21.1520.1520","article-title":"GATA2 mutations in pediatric myelodysplastic syndromes and bone marrow failure","volume":"122","author":"Hofmann","year":"2013","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0005","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1177\/2040620713487399","article-title":"Recognizing familial myeloid leukemia in adults","volume":"4","author":"Nickels","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0006","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/cam4.5026","article-title":"Mutational landscape and clinical outcome of pediatric acute myeloid leukemia with 11q23\/KMT2A rearrangements","volume":"12","author":"Yuen","year":"2023","journal-title":"Cancer Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0007","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2018-10-844662","article-title":"Genetic predisposition to MDS: clinical features and clonal evolution","volume":"133","author":"Kennedy","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0008","doi-asserted-by":"crossref","unstructured":"Atluri H and Godley LA. Germline testing in hematopoietic malignancies: whom to test, when, how, and why. Adv Oncol. doi: 10.1016\/j.yao.2025.01.005.","DOI":"10.1016\/j.yao.2025.01.005"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0009","article-title":"Genetic and clinical spectrum of SAMD9 and SAMD9L syndromes: from variant interpretation to patient management","author":"Sahoo","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0010","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1038\/s41375-021-01212-6","article-title":"Pediatric MDS and bone marrow failure-associated germline mutations in SAMD9 and SAMD9L impair multiple pathways in primary hematopoietic cells","volume":"35","author":"Thomas","year":"2021","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0011","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41591-021-01511-6","article-title":"Clinical evolution, genetic landscape and trajectories of clonal hematopoiesis in SAMD9\/SAMD9L syndromes","volume":"27","author":"Sahoo","year":"2021","journal-title":"Nat Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0012","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-024-01590-1","article-title":"Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients","volume":"17","author":"Halik","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0013","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ccr.2013.08.011","article-title":"Haploinsufficiency of <em>SAMD9L<\/em>, an endosome fusion facilitator, causes myeloid malignancies in mice mimicking human diseases with monosomy 7","volume":"24","author":"Nagamachi","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2020.101197","article-title":"Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9\/SAMD9L syndromes","volume":"33","author":"Sahoo","year":"2020","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0015","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1182\/blood.V89.10.3636","article-title":"Transcription factor GATA-2 is required for proliferation\/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation","volume":"89","author":"Tsai","year":"1997","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0016","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/371221a0","article-title":"An early haematopoietic defect in mice lacking the transcription factor GATA-2","volume":"371","author":"Tsai","year":"1994","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0017","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1182\/blood.2022017764","article-title":"The spectrum of GATA2 deficiency syndrome","volume":"141","author":"Calvo","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0018","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.chest.2021.05.046","article-title":"Pulmonary manifestations of GATA2 deficiency","volume":"160","author":"Marciano","year":"2021","journal-title":"Chest"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0019","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0020","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1182\/blood-2018-02-826461","article-title":"HSCT for GATA2 deficiency across the pond","volume":"131","author":"Hickstein","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0021","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/cid\/cit368","article-title":"MonoMAC syndrome in a patient with a GATA2 mutation: case report and review of the literature","volume":"57","author":"Camargo","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0022","doi-asserted-by":"crossref","first-page":"6092","DOI":"10.1182\/bloodadvances.2023010045","article-title":"Somatic mutational landscape of hereditary hematopoietic malignancies caused by germline variants in RUNX1, GATA2, and DDX41","volume":"7","author":"Homan","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0023","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-07-517151","article-title":"The evolution of cellular deficiency in GATA2 mutation","volume":"123","author":"Dickinson","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0024","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.hoc.2018.04.004","article-title":"Germline GATA2 mutation and bone marrow failure","volume":"32","author":"McReynolds","year":"2018","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0025","series-title":"Genetic\/Familial high-risk assessment: breast, ovarian, pancreatic, and prostate","year":"2025"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0026","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2015-04-641100","article-title":"Genomic analysis of germ line and somatic variants in familial myelodysplasia\/acute myeloid leukemia","volume":"126","author":"Churpek","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0027","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3324\/haematol.2016.149476","article-title":"Genetic features of myelodysplastic syndrome and aplastic anemia in pediatric and young adult patients","volume":"101","author":"Keel","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0028","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41467-017-01590-5","article-title":"The genomic landscape of pediatric myelodysplastic syndromes","volume":"8","author":"Schwartz","year":"2017","journal-title":"Nat Commun"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0029","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/bjh.14535","article-title":"The genomics of inherited bone marrow failure: from mechanism to the clinic","volume":"177","author":"Wegman-Ostrosky","year":"2017","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2024.101225","article-title":"Longitudinal clinical manifestations of Fanconi anemia: a systematized review","volume":"68","author":"Hoover","year":"2024","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0031","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1182\/hematology.2023000488","article-title":"When to consider inherited marrow failure syndromes in adults","volume":"2023","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0032","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.3324\/haematol.2019.222877","article-title":"Characterization and genotype-phenotype correlation of patients with Fanconi anemia in a multi-ethnic population","volume":"105","author":"Steinberg-Shemer","year":"2020","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0033","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.gim.2021.08.013","article-title":"Risk of cancer in heterozygous relatives of patients with Fanconi anemia","volume":"24","author":"McReynolds","year":"2022","journal-title":"Genet Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0034","first-page":"731","article-title":"Fanconi anemia diagnosis and the diepoxybutane (DEB) test","volume":"21","author":"Auerbach","year":"1993","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0035","article-title":"Diagnosis of Fanconi anemia by diepoxybutane analysis","volume":"85","author":"Auerbach","year":"2015","journal-title":"Curr Protoc Hum Genet"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0036","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/hematology.2022000393","article-title":"Modern management of Fanconi anemia","volume":"2022","author":"Dufour","year":"2022","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0037","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1182\/hematology.2023000490","article-title":"Clinical manifestations of telomere biology disorders in adults","volume":"2023","author":"Niewisch","year":"2023","journal-title":"Hematology"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0038","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1167848","article-title":"Telomere biology: from disorders to hematological diseases","volume":"13","author":"Roka","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0039","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.ajhg.2022.06.014","article-title":"Germline thymidylate synthase deficiency impacts nucleotide metabolism and causes dyskeratosis congenita","volume":"109","author":"Tummala","year":"2022","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0040","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/blood-2014-05-526285","article-title":"Bone marrow failure and the telomeropathies","volume":"124","author":"Townsley","year":"2014","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0041","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1159\/000540109","article-title":"Inherited telomere biology disorders: pathophysiology, clinical presentation, diagnostics, and treatment","volume":"51","author":"Rolles","year":"2024","journal-title":"Transfus Med Hemother"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0042","doi-asserted-by":"crossref","first-page":"49","DOI":"10.5045\/br.2022.2022012","article-title":"Overview of inherited bone marrow failure syndromes","volume":"57","author":"Park","year":"2022","journal-title":"Blood Res"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0043","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1038\/nprot.2006.263","article-title":"Flow cytometry and FISH to measure the average length of telomeres (flow FISH)","volume":"1","author":"Baerlocher","year":"2006","journal-title":"Nat Proto"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0044","doi-asserted-by":"crossref","first-page":"4108","DOI":"10.1182\/blood-2023-190629","article-title":"Telomere length testing of lymphocytes alone by flow-FISH is a highly sensitive and specific test to screen for a telomere biology disorder in a cohort of children and very young adults with bone marrow failure","volume":"142","author":"DeCleene","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0045","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3324\/haematol.2011.055269","article-title":"Telomere length is associated with disease severity and declines with age in dyskeratosis congenita","volume":"97","author":"Alter","year":"2012","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0046","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00112","article-title":"Diamond-Blackfan anemia predisposing to myelodysplastic syndrome in early adulthood","author":"Simkins","year":"2017","journal-title":"JCO Precis Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0047","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1182\/hematology.2021000314","article-title":"Diamond-blackfan anemia","volume":"2021","author":"Da Costa","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0048","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1182\/blood-2010-02-251090","article-title":"How I treat Diamond-Blackfan anemia","volume":"116","author":"Vlachos","year":"2010","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0049","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41375-023-02101-w","article-title":"Perspectives of current understanding and therapeutics of Diamond-Blackfan anemia","volume":"38","author":"Liu","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0050","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1016\/S2352-3026(24)00063-2","article-title":"Diagnosis, treatment, and surveillance of Diamond-Blackfan anaemia syndrome: international consensus statement","volume":"11","author":"Wlodarski","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0051","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1182\/blood.V128.22.333.333","article-title":"Myelodysplastic syndrome and gastrointestinal carcinomas characterize the cancer risk in Diamond Blackfan anemia: a report from the Diamond Blackfan Anemia Registry","volume":"128","author":"Vlachos","year":"2016","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0052","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.3324\/haematol.2023.282949","article-title":"Shwachman-Diamond syndromes: clinical, genetic, and biochemical insights from the rare variants","volume":"108","author":"Kawashima","year":"2023","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0053","series-title":"Statpearls","article-title":"Shwachman-Diamond syndrome","author":"Farooqui","year":"2024"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0054","doi-asserted-by":"crossref","first-page":"e238","DOI":"10.1016\/S2352-3026(19)30206-6","article-title":"Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study","volume":"7","author":"Myers","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0055","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1182\/blood-2024-206661","article-title":"Incidence of myeloid malignancy in Shwachman-Diamond syndrome: an international cohort study","volume":"144","author":"Myers","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0056","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/MOH.0000000000000479","article-title":"Mechanisms of leukemic transformation in congenital neutropenia","volume":"26","author":"Link","year":"2019","journal-title":"Curr Opin Hematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0057","first-page":"45","article-title":"Analysis of risk factors for myelodysplasias, leukemias and death from infection among patients with congenital neutropenia. Experience of the French Severe Chronic Neutropenia Study Group","volume":"90","author":"Donadieu","year":"2005","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0058","doi-asserted-by":"crossref","first-page":"4628","DOI":"10.1182\/blood-2005-11-4370","article-title":"The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapy","volume":"107","author":"Rosenberg","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0059","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2141.2010.08216.x","article-title":"Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy","volume":"150","author":"Rosenberg","year":"2010","journal-title":"Br J Haematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1182\/blood-2006-02-004275","article-title":"Incidence of CSF3R mutations in severe congenital neutropenia and relevance for leukemogenesis: results of a long-term survey","volume":"109","author":"Germeshausen","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0061","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1182\/blood.2022017735","article-title":"Hereditary platelet disorders associated with germ line variants in RUNX1, ETV6, and ANKRD26","volume":"141","author":"Homan","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0062","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1182\/bloodadvances.2021004653","article-title":"B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations","volume":"5","author":"Six","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0063","doi-asserted-by":"crossref","DOI":"10.1172\/JCI147898","article-title":"Germline RUNX1 variation and predisposition to childhood acute lymphoblastic leukemia","volume":"131","author":"Li","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0064","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1097\/HS9.0000000000000203","article-title":"Germline RUNX1 intragenic deletion: implications for accurate diagnosis of FPD\/AML","volume":"3","author":"Duployez","year":"2019","journal-title":"Hemasphere"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0065","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.3324\/haematol.2021.278762","article-title":"The RUNX1 database (RUNX1db): establishment of an expert curated RUNX1 registry and genomics database as a public resource for familial platelet disorder with myeloid malignancy","volume":"106","author":"Homan","year":"2021","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0066","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/bloodadvances.2023011165","article-title":"Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy","volume":"8","author":"Yu","year":"2024","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0067","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/bloodadvances.2020002709","article-title":"Restoring RUNX1 deficiency in RUNX1 familial platelet disorder by inhibiting its degradation","volume":"5","author":"Krutein","year":"2021","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0068","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2023019746","article-title":"Natural history study of patients with familial platelet disorder with associated myeloid malignancy","volume":"142","author":"Cunningham","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0069","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1182\/bloodadvances.2019000901","article-title":"RUNX1-mutated families show phenotype heterogeneity and a somatic mutation profile unique to germline predisposed AML","volume":"4","author":"Brown","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0070","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1182\/bloodadvances.2017013037","article-title":"Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies","volume":"2","author":"Drazer","year":"2018","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0071","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.3324\/haematol.2022.282049","article-title":"ANKRD26 is a new regulator of type I cytokine receptor signaling in normal and pathological hematopoiesis","volume":"108","author":"Basso-Valentina","year":"2023","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0072","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1172\/JCI71861","article-title":"Thrombocytopenia-associated mutations in the ANKRD26 regulatory region induce MAPK hyperactivation","volume":"124","author":"Bluteau","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0073","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1182\/blood.2019852418","article-title":"ETV6-related thrombocytopenia and leukemia predisposition","volume":"134","author":"Di Paola","year":"2019","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0074","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.3324\/haematol.2016.147496","article-title":"Clinical and pathogenic features of ETV6-related thrombocytopenia with predisposition to acute lymphoblastic leukemia","volume":"101","author":"Federica","year":"2016","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0075","doi-asserted-by":"crossref","first-page":"9114","DOI":"10.4081\/hr.2021.9114","article-title":"Germline CEBPA mutation in familial acute myeloid leukemia","volume":"13","author":"Boada","year":"2021","journal-title":"Hematol Rep"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0076","unstructured":"Tawana K and Fitzgibbon J. CEBPA-associated familial acute myeloid leukemia (AML). In: Adam MP, Feldman J, Mirzaa GM, et al. (eds) GeneReviews(R). Seattle (WA), 1993."},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0077","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2015-05-647172","article-title":"Disease evolution and outcomes in familial AML with germline CEBPA mutations","volume":"126","author":"Tawana","year":"2015","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0078","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a003210","article-title":"Hematologic malignancies and Li-Fraumeni syndrome","volume":"5","author":"Swaminathan","year":"2019","journal-title":"Cold Spring Harb Mol Case Stud"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0079","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.5858\/2009-0015-OA.1","article-title":"Myelodysplastic syndromes arising in patients with germline TP53 mutation and Li-Fraumeni syndrome","volume":"134","author":"Talwalkar","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0080","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1200\/JCO.2014.59.5728","article-title":"Revisiting Li-Fraumeni syndrome from TP53 mutation carriers","volume":"33","author":"Bougeard","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0081","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026286","article-title":"TP53 mutations in hypodiploid acute lymphoblastic leukemia","volume":"7","author":"Comeaux","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0082","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1158\/1078-0432.CCR-24-3301","article-title":"Update on cancer screening recommendations for individuals with Li\u2013Fraumeni Syndrome","volume":"31","author":"Achatz","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0083","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1158\/1078-0432.CCR-17-0408","article-title":"Cancer screening recommendations for individuals with Li-Fraumeni syndrome","volume":"23","author":"Kratz","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0084","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.breast.2022.06.003","article-title":"Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51D","volume":"65","author":"Graffeo","year":"2022","journal-title":"Breast"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0085","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1086\/426403","article-title":"CHEK2 is a multiorgan cancer susceptibility gene","volume":"75","author":"Cybulski","year":"2004","journal-title":"Am J Hum Genet"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0086","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat Genet"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0087","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1038\/s41375-024-02253-3","article-title":"Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer","volume":"38","author":"Arends","year":"2024","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0088","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-025-02635-1","article-title":"Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants","author":"Stubbins","year":"2025","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0089","article-title":"Current understanding of DDX41 mutations in myeloid neoplasms","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0090","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.clml.2016.04.001","article-title":"Evaluation of patients and families with concern for predispositions to hematologic malignancies within the hereditary hematologic malignancy clinic (HHMC)","volume":"16","author":"DiNardo","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0091","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood.2022017715","article-title":"DDX41-associated susceptibility to myeloid neoplasms","volume":"141","author":"Makishima","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0092","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.ccell.2015.03.017","article-title":"Inherited and somatic defects in DDX41 in myeloid neoplasms","volume":"27","author":"Polprasert","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110856","article-title":"DDX41 is required for cGAS-STING activation against DNA virus infection","volume":"39","author":"Singh","year":"2022","journal-title":"Cell Rep"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.992340","article-title":"Unique role of DDX41, a DEAD-box type RNA helicase, in hematopoiesis and leukemogenesis","volume":"12","author":"Shinriki","year":"2022","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0095","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2024.286887","article-title":"Overall cancer risk in people with deleterious germline DDX41 variants","author":"Korotev","year":"2025","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0096","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1182\/blood.2023020209","article-title":"Prevalence and significance of DDX41 gene variants in the general population","volume":"142","author":"Cheloor Kovilakam","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0097","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.exphem.2016.04.017","article-title":"Biological implications of somatic DDX41 p.R525H mutation in acute myeloid leukemia","volume":"44","author":"Kadono","year":"2016","journal-title":"Exp Hematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0098","doi-asserted-by":"crossref","first-page":"7346","DOI":"10.1182\/bloodadvances.2023011389","article-title":"The clinical and genomic landscape of patients with DDX41 variants identified during diagnostic sequencing","volume":"7","author":"Maierhofer","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0099","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/bloodadvances.2021005738","article-title":"Genetic features and clinical outcomes of patients with isolated and comutated DDX41-mutated myeloid neoplasms","volume":"6","author":"Alkhateeb","year":"2022","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0100","article-title":"Next-generation sequencing of DDX41 in myeloid neoplasms leads to increased detection of germline alterations","volume":"10","author":"Bannon","year":"2020","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0101","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/ajcp\/aqab027","article-title":"Clinical and pathologic spectrum of DDX41-mutated hematolymphoid neoplasms","volume":"156","author":"Goyal","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0102","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/bloodadvances.2022008172","article-title":"Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies","volume":"7","author":"Saygin","year":"2023","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0103","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.31505","article-title":"Case of refractory classic Hodgkin lymphoma with a germline pathogenic monoallelic variant in the TNFRSF13B gene","volume":"72","author":"Camacho-Arias","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0104","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/hon.3212","article-title":"TNFRSF13B gene mutation in familial acute myeloid leukemia: a new piece in the complex scenario of hereditary predisposition?","volume":"41","author":"Cumbo","year":"2023","journal-title":"Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0105","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1080\/10428194.2020.1802448","article-title":"Germline JAK2 V617F mutation as a susceptibility gene causing myeloproliferative neoplasm in first-degree relatives","volume":"61","author":"Park","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0106","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1056\/NEJMc1200349","article-title":"Germline JAK2Mutation in a family with hereditary thrombocytosis","volume":"366","author":"Mead","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0107","first-page":"485","article-title":"Unraveling the germline inheritance of the JAK2 F556V gene mutation in familial thrombocythemia: a comprehensive analysis of 11 family members and potential implications for surveillance","volume":"110","author":"Meggendorfer","year":"2025","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0108","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/bloodadvances.2024013661","article-title":"JAK2 p.R564 germ line variants associated with hereditary thrombocythemia and hematologic neoplasms","volume":"9","author":"Stewart","year":"2025","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0109","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ajh.23614","article-title":"A novel germline JAK2 mutation in familial myeloproliferative neoplasms","volume":"89","author":"Rumi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0111","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJMoa2413361","article-title":"Tumor-infiltrating clonal hematopoiesis","volume":"392","author":"Pich","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0112","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1158\/1078-0432.CCR-22-2598","article-title":"CHIP happens: clonal hematopoiesis of indeterminate potential and its relationship to solid tumors","volume":"29","author":"Reed","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0113","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/cas.15294","article-title":"CHIP-associated mutant ASXL1 in blood cells promotes solid tumor progression","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0114","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/s41586-020-2819-2","article-title":"Inherited causes of clonal haematopoiesis in 97,691 whole genomes","volume":"586","author":"Bick","year":"2020","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0115","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1182\/blood-2023-182423","article-title":"Genetic determinants of clonal hematopoiesis and progression to hematologic malignancies in 479,117 individuals","volume":"142","author":"Liu","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0116","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1038\/s41586-023-05806-1","article-title":"Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis","volume":"616","author":"Weinstock","year":"2023","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0117","unstructured":"Network NCC. (2025, accessed June 23 2025 2025)."},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0118","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s11899-022-00684-2","article-title":"Approach toward germline predisposition syndromes in patients with hematologic malignancies","volume":"17","author":"Atluri","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0119","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1002\/cncr.31331","article-title":"Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels","volume":"124","author":"DiNardo","year":"2018","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0120","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a036541","article-title":"Cancer genetic counseling-current practice and future challenges","volume":"10","author":"Schienda","year":"2020","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0121","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/rmir.12195","article-title":"Genetic testing and insurance implications: surveying the US general population about discrimination concerns and knowledge of the Genetic Information Nondiscrimination Act (GINA)","volume":"24","author":"Prince","year":"2021","journal-title":"Risk Manag Insur Rev"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0122","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1182639","article-title":"Challenges associated with the identification of germline variants on myeloid malignancy genomic profiling-a Singaporean experience","volume":"13","author":"Chin","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0123","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3389\/fped.2017.00252","article-title":"Clinical assessment and diagnosis of germline predisposition to hematopoietic malignancies: the University of Chicago experience","volume":"5","author":"Desai","year":"2017","journal-title":"Front Pediatr"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0124","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.hoc.2019.10.002","article-title":"Genetic predisposition to myelodysplastic syndrome in clinical practice","volume":"34","author":"Schratz","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0125","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0126","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1182\/bloodadvances.2020003304","article-title":"Accurate germline RUNX1 variant interpretation and its clinical significance","volume":"4","author":"Feurstein","year":"2020","journal-title":"Blood Adv"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0127","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_432218","article-title":"Germline predisposition in hematologic malignancies: testing, management, and implications","volume":"44","author":"Godley","year":"2024","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0128","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1002\/humu.24374","article-title":"Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders","volume":"43","author":"DeRoin","year":"2022","journal-title":"Hum Mutat"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0129","first-page":"3143","article-title":"How I communicate with patients and families about germ line genetic information","volume":"141","author":"Hamilton","year":"2023","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0130","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1038\/leu.2016.23","article-title":"Donor cell-derived hematological malignancy: a survey by the Japan Society for Hematopoietic Cell Transplantation","volume":"30","author":"Kato","year":"2016","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0131","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1182\/blood-2018-07-861070","article-title":"Donor-derived MDS\/AML in families with germline GATA2 mutation","volume":"132","author":"Galera","year":"2018","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0132","article-title":"Clinical considerations at the intersection of hematopoietic cell transplantation and hereditary hematopoietic malignancy","volume":"13","author":"O'Connor","year":"2023","journal-title":"Front Oncol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0133","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1002\/ajh.27070","article-title":"Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants","volume":"98","author":"Bataller","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0134","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1182\/blood.2024026925","article-title":"Refined ELN 2024 risk stratification improves survival prognostication following venetoclax-based therapy in AML","volume":"144","author":"Lachowiez","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0135","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/s41375-021-01404-0","article-title":"AML with germline DDX41 variants is a clinicopathologically distinct entity with an indolent clinical course and favorable outcome","volume":"36","author":"Li","year":"2022","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0136","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1182\/blood.2024024944","article-title":"Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine","volume":"144","author":"D\u00f6hner","year":"2024","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0137","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1080\/10428194.2023.2220457","article-title":"Clinical guideline variability in the diagnosis of hereditary hematopoietic malignancy syndromes","volume":"64","author":"Hamidi","year":"2023","journal-title":"Leuk Lymphoma"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0138","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2017-02-735290","article-title":"Genetic predisposition to hematologic malignancies: management and surveillance","volume":"130","author":"Godley","year":"2017","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2025.08.002_bib0139","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3324\/haematol.2017.178111","article-title":"Cancer in the National Cancer Institute inherited bone marrow failure syndrome cohort after fifteen years of follow-up","volume":"103","author":"Alter","year":"2018","journal-title":"Haematologica"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196325000356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T13:28:26Z","timestamp":1765632506000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196325000356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":139,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S0037196325000356"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Germline predispositions to myeloid malignancies: Across the lifespan","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2025.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}